Ann: Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides, page-80

What other anomalies re "unusual" results for paxol+placibo? Well, these are the scinarios/question scientists anticipate but unfortunately retail investors do not! I am absolutely certain yhe team will NOT spare the horses in milking every bit of information in the next few weeks to answer that very question, AND of course zooming in on the subgroup(s) for which Efti outperformed above expected (that lifted the average against the subgroup that perhaps performed average - but seemingly not below).

So, lets see what the full analysis has to say in a few weeks time.

Good news again: 1) we are lucky to be alive and 2) the results IMO cannot be worse than announced upon full analysis 3) the results even as they are, WERE encouraging 4) I am not as concerned with my investment (even if this were the end of it) in this stock that is trying to save lives, as A LOT OF other stocks that are there to purely support greedy lifestyler BoDs some with no, zilch moral.